Inhibition of Clostridium difficile Toxin A–Induced Colitis in Rats by APAZA
- 92 Downloads
A new compound, APAZA, consisting of a molecule of 5-aminosalicylic acid linked to one molecule of 4-aminophenylacetic acid by an azo bond, was tested for its ability to inhibit acute colitis in rats caused by Clostridium difficile toxin A. When administered chronically for 5 days in drinking water, APAZA significantly inhibited toxin A–induced myeloperoxidase activity, luminal fluid accumulation, and structural damage to the colon at doses of from 1 to 100 mg/kg⋅day. For comparison, sulfasalazine was administered in identical doses and was found to significantly inhibit toxin A–induced colitis only at the dose of 100 mg/kg⋅day. When 4-aminophenylacetic acid alone was administered chronically in drinking water, it also inhibited toxin A–induced colonic inflammation at a dose of 100 mg/kg⋅day. In order to determine if 4-aminophenylacetic acid has a direct anti-inflammatory effect on the colon rather than a systemic effect, 4-aminophenylacetic acid was administered acutely to surgically prepared isolated colonic segments by intraluminal injection in anesthetized rats 30 min before toxin A was injected. 4-Aminophenylacetic acid strongly and significantly inhibited toxin A–induced colitis in this experiment at doses as low as 10 μg/segment. It is concluded that APAZA is a potent inhibitor of toxin A–induced colonic inflammation in rats and that its constituent, 4-aminophenylacetic acid, is responsible for this increased protection against colitis compared to the 5-aminosalicylic acid component of sulfasalazine.
Keywords:5-aminosalicylic acid 4-aminophenylacetic acid inflammation colitis animal model.
Unable to display preview. Download preview PDF.
- 1.Jafri S, Pasricha PJ: Agents used for diarrhea, constipation, and inflammatory bowel disease: Agents used for biliary and pancreatic disease. In Goodman & Gilman’s The Pharmacological Basis of Therapeutics. JG Hardman, LE Limbird, AG Gilman (eds). New York, McGraw–Hill, 2001, pp 1037–1058Google Scholar
- 6.Merlin D, Si-Tahar M, Sitaraman SV, Eastburn K, Williams I, Liu X, Hediger MA, Madara JL: Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterol 120:1666–1679, 2001CrossRefGoogle Scholar
- 8.Ekwuribe NN, Riggs-Sauthier JA: Immunoregulatory compounds and derivatives and methods of treating diseases therewith U.S. patent 942464, 2003Google Scholar